Previous research has shown that TP53 mutations were mutually exclusive with FGFR3 mutations in bladder cancer [26], whereas their co-occurrence with ERBB2 alterations was associated with a worse prognosis in breast cancer [27]. This evidence concerns the gene ERBB2 and urinary bladder cancer.